Triple-Negative Breast Cancers (TNBCs)

Rodrigo Arrangoiz MS, MD, FACS, FSSO

slide4

  • Triple-negative breast cancers (TNBCs):
    • Negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.
    • They account for approximately 15% to 20% of all female breast cancers.
    • TNBC is heterogeneous based on gene expression microarray, and identification of TNBC subtypes and their behavior has the potential to enable more targeted, neoadjuvant, and adjuvant interventions.
    • TNBCs usually are higher grade (Nottingham score 3) and are more common in younger, Hispanic, and African American women.
    • They are more aggressive, have an increased likelihood of distant disease and mortality.
    • They are larger at presentation, and are more likely to be associated with lymph node metastases.
    • Patients with TNBC are at a higher risk for visceral metastases early in the course of the disease.
    • Genetic risk evaluation is recommended for patients with TNBC diagnosed at or before 60 years of age.
    • Surgical management may be influenced by gene testing results.
    • Standard adjuvant chemotherapy is anthracycline or taxane based.

TNBC-slide2_0

 

tripple-neg

 

Rodrigo Arrangoiz MS, MD, FACS a surgical oncologist and is a member of Sociedad Quirúrgica S.C at the America British Cowdray Medical Center in Mexico City:

  • He is an expert in the management of breast cancer.

    • If you have any questions about the management of triple negative breast cancer patients please fill free to contact Dr. Arrangoiz.

20d943b1-6f20-49c3-9754-2f3756051c93

Training:

• General surgery:

• Michigan State University:

• 2004 al 2010

• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:

• Fox Chase Cancer Center (Filadelfia):

• 2010 al 2012

• Masters in Science (Clinical research for health professionals):

• Drexel University (Filadelfia):

• 2010 al 2012

• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:

• IFHNOS / Memorial Sloan Kettering Cancer Center:

• 2014 al 2016

#Arrangoiz

#Surgeon

#Cirujano

#SurgicalOncologist

#CirujanoOncologo

#BreastSurgeon

#CirujanodeMama

#CancerSurgeon

#CirujanodeCancer

http://www.sociedadquirurigca.com

 

img_0832-2img_0833-2img_0834-2img_0835-2img_0836-2img_0837-2

Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a comment